Overview

Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2029-05-31

Target enrollment:

Participant gender:

Summary

This study is a phase 2 open-label, multicenter clinical study to evaluate the efficacy and safety SKB264 in combination with pembrolizumab in patients with unresectable stage III non-small cell lung cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Hunan Province Tumor Hospital

Treatments:

pembrolizumab